Keyword: Bigfoot Biomedical
CMS covers traditional insulin pumps, but not tubeless patch pumps, causing concern around innovation as well as patient access.
The series B gives Bigfoot the financial muscle to move its automated insulin infusion device into a pivotal clinical trial in the U.S. next year.
The agreement sets Bigfoot up to start a pivotal trial of a version of its delivery system that incorporates the Abbott technology next year.
Bigfoot Biomedical reeled in $35.5 million in Series A funding, which it will use to push its automated insulin delivery service through the last stages of development.